News

Hepatitis B Prevalent in San Diego's Asian Communities.

To view the video: click here

Guilty verdicts delivered in hepatitis C outbreak trial

To view the video: please click here

The Silent Pandemic: Tackling Hepatitis C with Policy Innovation

The Silent Pandemic: Tackling Hepatitis C with Policy Innovation was developed by the Economist Intelligence Unit and investigates the challenges posed by the hepatitis C virus and how systemic policy innovation can minimise its impact. The report found:

  • A need for better surveillance and epidemiology. As one official interviewed for this study noted, “we don’t have a real understanding of the magnitude” of the challenge HCV presents. Too few countries – developed or developing – have recently conducted the epidemiological studies necessary for good policymaking at a national, let alone a local level. According to the World Hepatitis Alliance, a patient group, within the European Union only the Netherlands has good data on hepatitis B and C, while in 16 EU countries the data are either poor or non-existent.
  • Significant barriers to addressing the disease exist, including a lack of scientific knowledge, poor public awareness and delay of treatment owing to cost and side effects. Despite substantial scientific progress since the discovery of HCV in 1989 and the availability of increasingly effective treatments with improving cure rates, some basic elements of its biology remain a mystery, such as why some people develop end-stage conditions and others do not. At the same time, the public remains largely ill-informed about HCV: a survey by the European Liver Patients Association found that only 20% of those diagnosed had heard of hepatitis B or C before being told they had it.
  • For too many developing countries, the healthcare system itself remains a leading vector of transmission for hepatitis C. In 2008 the WHO found that for those low-income countries where data are available, only 53% of blood was screened for the virus in a quality-assured manner, and that in 39 countries donated blood was not routinely screened at all.
  • The high incidence and prevalence of HCV among injecting drug users in developed countries presents prevention and treatment problems and has stigmatised the disease and presents a series of related problems in addressing HCV.
  • Facing up to the challenges posed by HCV requires a co-ordinated strategy covering a range of areas. HCV will not go away on its own. Countries which have had the most success so far have tended to focus on the problem in a co-ordinated way, rather than on one individual aspect. Each country will have different needs and resources, but all should consider obtaining strong data, raising awareness of the disease and focusing on prevention.

The launch of the report included presentations from Paul Kielstra from the Economist Intelligence Unit; Charles Gore, President of the World Hepatitis Alliance; Jack Wallace, Executive Member of the Coalition for the Eradication of Viral Hepatitis in Asia and the Pacific (CEVHAP) and Prof. David Goldberg, Head of Scottish Hepatitis C Programme. The report was supported by Janssen Pharmaceutica NV and its findings are based on extensive desk research and interviews conducted with leading global medical and policy experts.

To read the report click here

To watch the webcast click here

Remembering a Giant: R. Palmer Beasley

Dr. R. Palmer Beasley's passing is a tremendous loss for the hepatitis community. He was a member of CEVHAP and Palmer and I were friends for nearly 40 years. I knew him very well, because he worked in Taiwan in 1970-80's and we both had a common interest in hepatitis research. He contributed a lot to our understanding of the epidemiology of hepatitis B, the etiologic role of hepatitis B virus (HBV) in hepatocellular carcinoma (HCC), and the immunoprophylaxis of HBV infection. His landmark discovery of "vertical" transmission of HBV from carrier mothers to their infants in early 1970's paved the road of hepatitis B vaccination. Indeed, he and colleagues went on to show the efficacy of hepatitis B immune globulin and hepatitis B vaccine in this setting, which laid the foundation of hepatitis B immunization in newborns. It is now a regular practice worldwide and this will avert millions of deaths due to end-stage liver disease and HCC.

Although the control of hepatitis B is on the right track, there are still many hurdles in its implementation. While CEVHAP is working toward the eradication of viral hepatitis in our region, we will all remember the giant who has contributed so much to what we are doing now.

D S Chen
Chair

An article in The New York Times:
R. Palmer Beasley, Expert on Hepatitis B, Dies at 76

FaLang translation system by Faboba
>> PRESS RELEASES

 

2017

APASL 2017
English                        

2016

CEVHAP Asia Pacific Hepatitis Policy 2016 Survey finds Asia Pacific on path to eliminating viral hepatitis
APASL 2016
English

2015

WHD 2015
  English
  Chinese                        

Linkage between screening and treatment needed to improve hepatitis care in China 

  English                
  Chinese

 

 2014

WHD 2014
  English
  Chinese                        
APASL 2014
  English                        
  Chinese

2013

WHD 2013
  English
  Chinese                        

APASL 2013

CEVHAP welcomes the launch and dedicates their support to the Global Hepatitis Network 
 

2012 

WHD 2012

CEVHAP WHD 2012 Press Release
CEVHAP-NSW Health Joint
Press Release in Australia
 
APASL 2012
CEVHAP Symposium Announcement 
 

2011

WHD 2011
China (Chinese)
India
Indonesia (Bahasa)
CEVHAP-KASL WHD Joint
Press Release in Korea (Korean)
Malaysia
Hong Kong (English)
Hong Kong (Chinese)
Connect with usconnect with CEVHAP